TEL: (212)616-4899

TG Therapeutics, Inc. Loss Submission Form

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of TG Therapeutics, Inc. (NASDAQCM: TGTX) who purchased shares between June 4, 2018 and September 25, 2018. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.

In particular, the TG lawsuit alleges that (1) TG was involved in cleaning the data collected in the UNITY-CLL Trial; and as a result, was able to gain an understanding as to the efficacy of the combination therapy; (2) as a result of that data cleaning, TG knew the UNITY-CLL Trial had failed to meet its stated goal and as a result, the Company would not be able to seek accelerated approval; and (3) given that the UNITY-CLL Trial had failed to meet its stated goal, it was highly unlikely that the combination therapy would meet its primary endpoint of increased progression free survival.

Shareholders have until December 3, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

Keep Me Informed

The Klein Law Firm does not share your information with others. There is no cost or obligation. This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.